Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

779.67 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
59 60 Next >
News headline image
Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space. 
Via MarketBeat
News headline image
1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street ↗
Via The Motley Fool
News headline image
Healthcare And Biotech Stocks Continue Their Slide ↗
Biotech shares continued their slide which began in early November and got no help from small caps which also sold off through December. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
What 25 Analyst Ratings Have To Say About Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Regeneron Pharmaceuticals Unusual Options Activity ↗
 
Via Benzinga
News headline image
Are You Ready To Trade Biotech Stocks At The Cusp Of A Bear Market? ↗
It’s not a bear market for biotech yet it just feels that way because recent trends are down and healthcare stocks are not a stabilizing force. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More ↗
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
News headline image
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking ↗
 
Via Benzinga
News headline image
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study ↗
Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA submission expected in Q1 2025. 
Via Benzinga
News headline image
Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts ↗
Wall Street began Tuesday’s session on a weaker note, with major indices slipping after November's robust retail sales report reignited investor concerns that the Federal Reserve might hold back... 
Via Benzinga
Topics Economy
News headline image
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Peering Into Regeneron Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Check Out What Whales Are Doing With REGN ↗
 
Via Benzinga
News headline image
28 Analysts Have This To Say About Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? ↗
The weight-loss drugs space continues to heat up. Here's the latest news from the segment. 
Via Investor's Business Daily
News headline image
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money' ↗
Navitas Semiconductor is losing money according to Jim Cramer. LandBridge Company is a winner, while Regeneron is facing sales challenges. 
Via Benzinga
News headline image
It’s Been A Tough Month For Healthcare Stocks ↗
It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues. 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Not-So-Big Pharma ↗
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration. 
Via Talk Markets
News headline image
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease ↗
Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a decision expected by April 2025. 
Via Benzinga
News headline image
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Top Growth Stocks to Buy on the Dip ↗
Their recent issues are nothing to fret over for investors focused on the long game. 
Via The Motley Fool
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.